[Clinical studies on cefotaxime (CTX, HR 756) in obstetrics and gynecology (author's transl)].
In vivo transfer and therapeutic efficacy of a new cephalosporin derivative, cefotaxime, which is stable against beta-lactamase hydrolysis, have studied in gynecology field. The following results have been obtained. (1) The level of cefotaxime transferred to uterus artery and to uterus was higher than its MIC against majority of Gram-negative bacilli, such as E. coli. (2) Transfer of this drug to umbilical blood was also satisfactory. (3) This drug as demonstrated its efficacy in treating 8 infection cases refractory to CET, CEZ and ABPC, out of which 3 had 'excellent' and 5 had 'good' results. (4) No side effect was evidenced in any of our patients. In conclusion, this drug has satisfactory tissue transfer as well as sufficient safety and excellent efficacy in treatment of gynecological infection cases.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D014599:Uterus / Q000378:metabolism
D002439:Cefotaxime